Harbour BioMed’s Post

We are pleased to welcome Yajie Li as Chief Medical Officer at Harbour BioMed. 👏 👏 Ms. Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs including Merck, Johnson & Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China (NMPA)/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas. In her new role, Ms. Li will lead clinical development, regulatory strategy, and medical affairs, supporting the continued growth of our pipeline and the delivery of impactful treatments to patients worldwide. Learn more: https://lnkd.in/gejyaNix #Leadership #ClinicalDevelopment #RegulatoryAffairs #Innovation